Caimed

Zika 2016-2017.Colombia, República Dominicana y Panamá

Se trata de una revisión concisa de la situación de Zika en Colombia, República Dominicana y Panamá para el 2016 - 2017 de acuerdo a los reportes de los entes oficiales de salud de cada país.


Caimed

Vacuna tetravalente contra el dengue reduce las infecciones sintomáticas y asintomáticas de dengue en niños y adolescentes sanos de entre 2 y 16 años en Asia y América Latina.

Se piensa que las personas asintomáticas infectadas con dengue desempeñan una función importante en la transmisión del virus del dengue. La efectividad contra las infecciones asintomáticas de dengue de la vacuna CYD-TDV tetravalente contra dengue que fue recientemente aprobada no se había evaluado previamente.


Caimed

A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic

The present study was a prospective observational study to evaluate the safety profile of Celtura®, a monovalent, cell culture-derived, inactivated subunit influenza vaccine prepared from A/California/07/2009(H1N1) with the adjuvant MF59®.


Caimed

Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects

Adjuvanted influenza vaccines can overcome the poor antibody response of conventional nonadjuvanted vaccines in the elderly. We evaluated the immunogenicity, safety and clinical effectiveness of an MF59®-adjuvanted trivalent influenza vaccine (aTIV) compared with a non-adjuvanted vaccine (TIV) in subjects ≥65 years old, with or without co-morbidities.


Caimed

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

In light of the increasing rate of dengue infections throughout the world despite vector-control measures, several dengue vaccine candidates are in development.


Caimed

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

A candidate tetravalent dengue vaccine is being assessed in three clinical trials involving more than 35,000 children between the ages of 2 and 16 years in Asian–Pacific and Latin American countries. We report the results of long-term follow-up interim analyses and integrated efficacy analyses.


Caimed

Prospective Cohort Study with Active Surveillance for Fever in Four Dengue Endemic Countries in Latin America

To prepare for a Phase III dengue vaccine efficacy trial, 20 investigational sites were selected for this observational study to identify dengue infections in a closed cohort (N = 3,000 children 9–16 years of age). Of 255 acute febrile episodes experienced by 235 children, 50 (21.3%) were considered serologically probable dengue, and 18 (7.7%) were considered virologically confirmed (i.e., dengue NS1 antigen positive) dengue cases. Considering the disease-free and at-risk period from study start to onset of symptoms, the overall incidence density of acute febrile episodes was 17.7 per 100 person-years of follow-up, ranging from 15.3 in Colombia to 22.0 in Puerto Rico. This study showed that all sites were capable of capturing and following up acute febrile episodes within a specific timeframe among the established cohort and to detect dengue cases.